Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening
Top Cited Papers
- 1 February 2015
- journal article
- practice guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 125 (2), 330-337
- https://doi.org/10.1097/aog.0000000000000669
Abstract
In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology or cotesting (cytology in combination with high-risk human papillomavirus [hrHPV] testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective U.S.-based registration study. Thirteen experts, including representatives from the Society of Gynecologic Oncology, the American Society for Colposcopy and Cervical Pathology, the American College of Obstetricians and Gynecologists, the American Cancer Society, the American Society of Cytopathology, the College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the U.S. Food and Drug Administration (FDA) for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for health care providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trialsThe Lancet, 2013
- Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in FinlandBMJ, 2012
- Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL StudyBritish Journal of Cancer, 2012
- The HPV test has similar sensitivity but more overdiagnosis than the Pap test—A randomised health services study on cervical cancer screening in FinlandInternational Journal of Cancer, 2012
- Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2012
- Primary high-risk HPV screening for cervical cancer in post-menopausal womenGynecologic Oncology, 2012
- HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implicationsBritish Journal of Cancer, 2012
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialThe Lancet Oncology, 2010
- 2006 Consensus Guidelines for the Management of Women With Abnormal Cervical Screening TestsJournal of Lower Genital Tract Disease, 2007
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999